Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03046355
Other study ID # HSC-MS-16-1053
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 13, 2017
Est. completion date March 18, 2019

Study information

Verified date June 2019
Source The University of Texas Health Science Center, Houston
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of the study is to determine whether labor induction at 37 weeks of pregnancy can improve the baby's health at birth when compared with delivery at a later point in the pregnancy.


Recruitment information / eligibility

Status Completed
Enrollment 21
Est. completion date March 18, 2019
Est. primary completion date March 18, 2019
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 39 Years
Eligibility Inclusion Criteria:

- Singleton pregnancy

- Gestational age 34 weeks 0 days to 37 weeks 0 days at time of enrollment

- Dating of pregnancy by last menstrual period consistent with an ultrasound, ultrasound <21 weeks and 6 days of gestation, or known date of conception in the setting of in vitro fertilization

- No known major anomalies (anomalies requiring surgery antenatally or in the neonatal period, anomalies not compatible with life as determined by the physician)

- FGR defined as estimated fetal weight (EFW) < 10th percentile by Hadlock formula with normal umbilical artery Doppler studies and normal amniotic fluid

Exclusion Criteria:

- Known major fetal anomalies

- Multiple gestation or selective reduction of multiple gestation after 14 weeks

- Previous stillbirth at term

- Indications for delivery at <39 weeks. Common examples include:

- Placenta previa

- Placenta accreta

- Vasa previa

- History of classical cesarean section or myomectomy

- Human immunodeficiency virus (HIV)

- Oligohydramnios (low amniotic fluid, defined as maximum vertical pocket <2.0cm)

- High-risk pregnancy as determined by the physician. Common examples include:

- Pre-gestational diabetes or gestational diabetes on medication

- Chronic hypertension on medication

- Maternal cardiac disease

- Asthma requiring oral steroids during pregnancy

- Chronic renal disease

- Antiphospholipid syndrome

- Hyperthyroidism

- Prior stillbirth

- Systemic lupus erythematous

- Hemoglobinopathies such as sickle cell disease

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Labor induction at 37.0 to 37.6 weeks of gestation
Diagnosis of FGR with induction at 37 weeks 0 days of gestation to 37 weeks and 6 days
Expectant monitoring until delivery
Diagnosis of FGR managed with expectant monitoring and delivery as indicated

Locations

Country Name City State
United States Bellaire - Memorial Hermann Houston Texas
United States Memorial Hermann Memorial City Medical Center Houston Texas
United States The University of Texas Health Science Center at Houston Houston Texas

Sponsors (1)

Lead Sponsor Collaborator
The University of Texas Health Science Center, Houston

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of children with birthweight less than the third percentile for gestational as assessed by NICHD nomograms NICHD is National Institute of Child Health and Human Development The NICHD nomogram will indicate their birth weight percentile based on their gestational age and ethnicity Immediately at birth
Secondary Number of children presenting with CNM Composite neo-natal morbidity (CNM) is any of the following: Apgar score <5 at 5 minutes, seizure, sepsis, hypoglycemia requiring intravenous treatment, mechanical ventilation, CPAP (continuous positive airway pressure) or high-flow nasal cannula for >2 hours, oxygen supplementation with FiO2 (fraction of inspired oxygen) >30% for >4 hours, death before discharge or IUFD (intrauterine fetal death). Up to 6 weeks after delivery
Secondary Number of women presenting with CMM Composite maternal morbidity (CMM) is any of the following: chorioamnionitis, transfusion of blood products, endometritis, wound infection or separation, deep venous thrombosis, pulmonary embolism, admission to the intensive care unit, or death. Rates of cesarean section as well as indications in each group will also be evaluated. Up to 6 weeks after delivery
Secondary Number of children delivered by cesarean section Immediately at birth
Secondary Number of children admitted to NICU NICU is neo-natal intensive care unit Up to 6 weeks after delivery
Secondary Number of children presenting with SGA SGA is small for gestational age when birthweight <10% for gestational age Immediately at birth
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05934318 - L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE) N/A
Recruiting NCT05601375 - Speckle Tracking Echocardiography in Infants, Prenatally and Postnatally
Recruiting NCT03662178 - Investigating the Structured Use of Ultrasound Scanning for Fetal Growth
Completed NCT05059093 - Developing and Testing AI Models for Fetal Biometry and Amniotic Volume Assessment in Fetal Ultrasound Scans.
Completed NCT03067298 - Prediction of Preeclampsia and Other Pregnancy Complications Following Combined Iterative Screening
Recruiting NCT01981824 - Prediction of Growth Restricted Fetuses Using Femur Length to Mid-thigh Circumference Ratio: A Case-control Study N/A
Recruiting NCT04215107 - Fetal Distribution of Feto-placental Blood Flow Related to Placental Nutrient Transport and Maternal Food Intake N/A
Completed NCT02189148 - First-trimester Prediction of Preeclampsia
Terminated NCT04084990 - Sleep Apnea and Fetal Growth Restriction Phase 3
Recruiting NCT04051567 - Low-dose Aspirin for Prevention of Adverse Pregnancy Outcomes in Twin Pregnancies Phase 4
Recruiting NCT04394611 - Metals and in Fetal Growth Restriction
Completed NCT01369940 - The NICHD Fetal Growth Study: Twin Gestations N/A
Not yet recruiting NCT03121196 - Social Deprivation and Pregnancy N/A
Recruiting NCT03177824 - Sildenafil Citrate for Treatment of Growth-restricted Fetuses Phase 3
Completed NCT02379832 - Pre-Eclampsia And Growth Restriction: a Longitudinal Study
Completed NCT02379494 - First Trimester Prediction of Preeclampsia and Fetal Growth Restriction N/A
Not yet recruiting NCT05848869 - Prostaglandins Versus Trans-cervical Balloon for Induction of Labor in Fetal Growth Restriction N/A
Recruiting NCT04438668 - Evaluation of the Safety and Performance of Centaflow N/A
Recruiting NCT05423665 - Speckle Tracking Echocardiography as a Tool for Early Diagnosis of Impaired Fetal Growth Twin Pregnancies
Not yet recruiting NCT06343051 - USCOM in Newly Diagnosed FGR Cases